Open Access

Langerhans cell sarcoma originating from left knee subcutaneous tissue: A case report and literature review

  • Authors:
    • Yaonan Zhang
    • Zongyang Qu
    • Fang Fang
  • View Affiliations

  • Published online on: September 27, 2016     https://doi.org/10.3892/ol.2016.5194
  • Pages: 3687-3694
  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Langerhans cell sarcoma (LCS) is a neoplastic proliferation of Langerhans cells with notably malignant cytological features. Reports of LCS are sparsely available in English literature; to the best of our knowledge, only 55 cases have been reported. The present study reports a case of LCS originating from subcutaneous tissue of the left knee in a 75‑year‑old man. The diagnosis of LCS was supported by the results of magnetic resonance imaging, histological and immunohistochemical studies. The tumor began to metastasize to inguinal lymph nodes and eventually involved multiple organs. Chemotherapy and radiotherapy were administered but were ineffective, and the patient died within 2 years of diagnosis. The present case should aid in expanding the currently available knowledge concerning LCS.

Introduction

The World Health Organization classifies Langerhans cell tumors into two types: Langerhans cell sarcoma (LCS) and Langerhans cell histiocytosis (LCH) (1). LCS is a neoplastic proliferation of Langerhans cells with markedly malignant cytological features, whereas LCH is proliferative disorder of Langerhans cells (1). LCS may occur in individuals of a broad age range, and is highly metastatic (2). The disease may involve multiple organs or tissues (3), including bone, lung, skin, lymph nodes, gallbladder, tonsil and other soft tissues. In the clinic, LCS is an extremely rare disease that is unfamiliar to dermatologists (2). The clinical behavior of the disease is aggressive and the overall survival rate for affected patient's is <50% (3). Several therapeutic regimens have been investigated for the treatment of LCS, including surgery, chemotherapy, radiation therapy and combined therapy (3). However, due to the limited number of cases reported in the literature to date, no standard effective therapy has been suggested for the treatment of LCS (3). Among LCS patients, the therapeutic outcomes vary depending on the extent of the disease. In addition, the prognosis of the disease is poor and relapses usually occur within the first 3 years after excision (3).

The current study reports one case of LCS that originated from the subcutaneous tissue of the left knee of a male patient. In addition, all reported cases of LCS available in the English literature are summarized.

Case report

A 75-year-old male patient was admitted to Beijing Hospital (Beijing, China) on November 4, 2010, complaining of an egg-sized mass located at the medial part of his left knee. The patient reported that the mass had gradually enlarged during the past two months and caused mild-to-moderate pain at night. The pain would somehow be relieved during the daytime and after taking non-steroidal anti-inflammatory drugs. The patient had a medical history that included tonsillectomy 55 years previously, subtotal thyroidectomy 40 years previously (pathology indicated a thyroid adenoma), partial prostatectomy 15 years previously (benign pathology), radical operation for colorectal cancer 5 years previously (pathology indicated intramucosal carcinoma) and a resection of mass of the buttock 4 years previously (pathology indicated an abscess).

Physical examination revealed a firm mass of ~3×3 cm on the patient's left knee. Inguinal lymph nodes were palpated on both sides and were found to be small, round and soft. X-ray imaging indicated hyperosteogeny in the knee joint and an ultrasound of the mass revealed a low-echo region in the subcutaneous tissue. Magnetic resonance imaging (MRI) revealed a mass measuring ~40×12×15 mm with a clear boundary in the subcutaneous tissue on the anterior-medial side of the patient's left patella (Fig. 1). The mass exhibited homogeneous signal isointensity relative to that of muscle on T1-weighted imaging (Fig. 1A), and predominantly signal hyperintensity on T2-weighted imaging (Fig. 1B). A number of small patchy hyperintense signals were observed within the mass (Fig. 1B).

The patient received a knee arthroscopic surgery on November 10, 2010. Grossly, a 4×3×2-cm, gray mass was identified, located subcutaneously and with a clear border. No infiltration into the joint space was observed. Thus, the patient underwent a surgical resection of the mass. A 4.8×3.6×1.2-cm specimen was obtained. The cut surface of the resected specimen was gray, soft, and had a pseudo-membrane. Histological examination of the specimen buy hematoxylin and eosin staining indicated an infiltrative tumor mass. The tumor cells were surrounded by abundant lymphocytes, plasma cells and eosinophils (Fig. 2). The neoplastic cells exhibited cytological atypia, hyperchromatic nuclei and prominent nucleoli. Nuclear grooving was also observed in some of the neoplastic cells (Fig. 2). Immunohistochemical stains were positive for cluster of differentiation (CD)1a (+; rabbit monoclonal antibody; catalog no. AC-0078; 1:200 dilution; Baili Biotechnology Co., Ltd., Changhun, China; Fig. 3A), CD68 (+; mouse monoclonal antibody; catalog no. Z-2071; 1:200 dilution; Zeta Corporation, Los Angeles, CA, USA; Fig. 3B), S-100 (++; rabbit polyclonal antibody; catalog no. NCL-L-S100p; 1:150 dilution; Leica Microsystems, Ltd., Milton Keynes, UK; Fig. 3C) and vimentin (+++; mouse monoclonal antibody; catalog no. 202M-96; 1:150 dilution; Cell Marque, Sigma-Aldrich, St. Louis, MO, USA). The tests were negative for desmin (mouse monoclonal antibody; catalog no. 243M-16; 1:100 dilution; Cell Marque, Sigma-Aldrich), CD30 (mouse monoclonal antibody; catalog no. UM800033; 1:200 dilution; Origene Techynologies Inc., Rockville, MD, USA), CD15 (mouse monoclonal antibody; catalog no. CM073C; 1:200 dilution; Biocare Medical LLC, Concord, CA, USA), actin (mouse monoclonal antibody; catalog no. 202M-96; 1:150 dilution; Cell Marque, Sigma-Aldrich), HMB-45 (mouse monoclonal antibody; catalog no. Z-2088; 1:150 dilution; Zeta Co., Ltd.), melan-A (mouse monoclonal antibody; catalog no. Z-2052; 1:200 dilution; Zeta Co., Ltd.) and myoglobin (mouse monoclonal antibody; catalog no. NCL-MYOGLOBIN; 1:150 dilution; Leica Microsystems, Ltd.). The Ki-67 index (mouse monoclonal antibody; catalog no. UM800033; 1:200 dilution; Origene Techynologies Inc.) was ~70% (Fig. 3D). Taken together, the histomorphological, immunohistochemical and MRI findings supported a diagnosis of LCS.

Following the surgery, local radiotherapy was proposed for the patient. Unfortunately, this planned therapy was abolished as the patient was suffering from septic arthritis and fever. However, a careful plan to follow up this patient was established. At ~6 months after the first surgery, a positron emission tomography-computed tomography (PET-CT) study of the patient revealed a tumor mass in the left inguinal lymph nodes. Surgical resection of the left inguinal lymph nodes was performed in another hospital, Peking Union Medical College Hospital (Beijing, China), due to practical reasons. LCS metastasis to the inguinal lymph nodes was confirmed by the subsequent pathological findings. Unexpectedly, the patient had developed septic arthritis and fever again. Following postoperative recovery, the patient received four cycles (21 days for one cycle) of chemotherapy with cyclophosphamide (1.4 g on day 1), epirubicin hydrochloride (120 mg on day 1), vindesine (4 mg on day 1) and prednisone (100 mg/day on days 1–5) at Peking Union Medical College Hospital.

In January 2012, a follow-up PET-CT scan was performed. A 4.2×3.3 cm soft tissue mass was detected beside the external iliac with a maximal standardized uptake value (SUVmax) of around 12.6. Several small lymph nodes located close to the mass had an SUVmax of ~11.5. Furthermore, the inguinal lymph nodes in the left groin also had high SUVs of 5.1–7.1. Between February and March 2012, the patient received left groin and lateral pelvis local radiotherapy (total dose, 6,000 cGy; 30 fractions over 47 days) at Peking Union Medical College Hospital. However, the treatment was ineffective, and the LCS was found to have metastasized into multiple organs and tissues (liver, omentum and ascites) 2 months later. The patient succumbed to the disease in November 2012.

Discussion

LCS is a rare neoplastic proliferation of Langerhans cells with notable malignant cytological features (3). Sparse reports of LCS are available in English literature; to the best of our knowledge, only 55 cases have been reported to date. The available reports are summarized, together with the present case, in Table I [(2) and references therein; (339)]. A search of Pubmed was performed to find these reports using the keyword ‘Langerhans cell sarcoma’ and manual screening was applied. In these cases, the age at diagnosis of LCS ranged from 11 months to 88 years, with a median age of 53 years, and a male:female ratio of 1.4:1. The collective findings also indicate that LCS is extremely aggressive and that it typically metastasizes to multiple organs or tissues.

Table I.

Summary of the reported Langerhans cell sarcoma cases.

Table I.

Summary of the reported Langerhans cell sarcoma cases.

CaseAuthor, yearGender/age, yearsSiteClinical historyDiagnostic techniquesTherapyOutcomeRef.
1Wood, 1984M/71Cutaneous, lungNAEM, X-rayCDied at 2 months(4)
2Elleder, 1986F/NACutaneous and mucosal tumorsNAEMNANA(5)
3Delabie, 1991F/23Inguinal, iliac and retroperitoneal adenopathies, skin lesions and interstitial lung involvementNAEM, cytogenetic studyCDied of disease(6)
4Tani, 1992F/49Skin, inguinal adenopathyNAEM, labCDied at 4 years(7)
5Lauritzen, 1994M/38Skin, lymph nodes, lungNANACPartial remission after 12 months(8)
6Itoh, 2001F/74Skin, axillary adenopathyRight hand erythema lasting a few yearsCT, EMS, R, CDied at 14 months(9)
7Pileri, 2002F/17Cervical, groin, iliac and retroperitoneal adenopathies, and systemic symptomsNAEMC, RACR(10)
8 M/46Submandibular and left cervical adenopathiesNAEMCAWD
9 M/28Fever, cytopenia, anterior mediastinal mass and hepatosplenomegalyNAEMNoneDied at 3 weeks
10 F/50SkinNAEMNANA
11 F/10SkinNAEMS, RACR
12 F/23Skin, lymph nodes, lungNAEMCDied at 2 years
13 F/65Generalized adenopathies, lung lesions and hepatosplenomegalyNAEMCDied of disease
14 M/72Fever, mediastinal and axillary adenopathies, lung nodules, rib fractures and central nervous system lesionsNAEMCDied of disease
15 F/50Polyostotic bone lesionsNAEMSACR
16Misery, 2005F/38SkinNALabSACR(11)
17Kawase, 2005M/59Spleen, skin, lymph nodes, bone marrowEssentially normal, splenomegaly, no hepatomegalyNoneCDied at 9 years(12)
18Kawase, 2005M/35Bone, lymph nodes, lung, liverNAX-ray, MRI, CTCDied at 4 years(12)
19Kawase, 2005F/62Spleen, lymph nodes, liver2-year multiple bone painX-ray, CTCDied at 10 months(12)
20Kawase, 2005M/60BoneNAX-ray, MRIRACR(12)
21Jülg, 2006M/81Mediastinal mass and interstitial lung involvementNACT, EMCDied at 1 month(13)
22Ferringer, 2006M/33Posterior thigh skin, lymph nodesNAEMCACR(14)
23Lee, 2014M/34LungSmoker, treated and cured pulmonary tuberculosisCTSACR(15)
24Diaz-Sarrio, 2007M/58Skin, lymph nodesLiver transplantation and immunosuppressive therapyX-ray, EMSACR(16)
25Bohn, 2007M/47Skin, lymph nodesNACT, EMS, R, CAWD(17)
26López-Ferrer, 2008M/67Cervical lymph nodeNANASNA(18)
27Sumida, 2008M/57Supraclavicular lymph nodeNALab, EM, IGHCDied at 7 months(19)
28Yoshimi, 2008F/53Skin, lymph nodes, lung, stomach, liver, spleen, kidneys, bone marrowLiver failure due to primary biliary cirrhosisCT, Lab, FDG-PETCDied at 5 months(20)
29Uchida, 2008M/72SkinOtherwise healthyFDG-PET, MRICACR(21)
30Zhao, 2009F/74Gallbladder, lymph nodesNAUltrasound, MRI, CTSACR(22)
31Langfort, 2009M/47Lung, lymph nodesSmoker, 30 packs/yearCT, EMS, CAWD(23)
32Diaz-Sarrio, 2007M/63Skin, lymph nodesLiver transplantation and immunosuppressive therapyPETC, RDied at 5 years(16)
33Nakayama, 2010M/62Cervical lymph node3-month neck swellingCT, FDG-PETRACR(24)
34Ratei, 2010M/20Supraclavicular lymph nodeACR from B-cell acute lymphoblastic leukemiaIGH, CTC, allo-PBSCTACR(25)
35Chen, 2012M/53Lung, lymphadenopathyHeavy smoker, severe coughPET-CTNANA(26)
36Muslimani, 2012F/66Left pyriform sinusHairy cell leukemiaPET-CT, cytogenetic study, IGHCDied of disease(27)
37Furmanczyk, 2012M/75Skin, bone marrow1-year leukemiaMRI, IGHS, R, CDied of disease(28)
38Shimizu, 2012F/67Inguinal lymph node, cervical nodeNACT, PETCACR(29)
39Wang, 2012M/41Multifocal cutaneous, anterior iliac spine, liver, lungNANAS, CDied at 1 year(30)
40Xu, 2012M/86Lymphadenopathy and splenomegalyDiabetes, 25-year arteritis and myocardial infarctionLab, CTS, RDied at 1 month(31)
41Yang, 2013M/52Lung, lymph nodes, ribHealthy smokerLab, PET-CTCAWD(32)
42Wang, 2013F/77Lymph nodes and nasopharyngeal recess mass1-month neck swelling and painEM, CTNoneDied at 2 weeks(2)
43Chang, 2013F/70Lymph nodeChronic myelogenous leukemia undergoing imatinib mesylate therapyLab, cytogenetic studyS, CACR(33)
44Chen, 2013F/68Inguinal lymph nodeChronic lymphocytic leukemiaCytogenetic studyCAWD(34)
45Chung, 2013F/11 mo.Fever, lymph nodesNALab, CT, MRICAWD(35)
46 F/17Fever, hepatosplenomegaly, petechiae, lymph nodes, liver, skinUnremarkable past medical and family historiesLab, CT, MRICAWD
47Keklik, 2013M/39NasopharynxNANACDied(36)
48Li, 2013M/48Ulcerated erythematous plaque on right knee, skin noduleNALabCACR(37)
49Sagransky, 2013M/54Subcutaneous nodules, neutropenic fever, Clostridium difficile colitisAcute myeloid leukemiaNACACR(38)
50 F/63SkinUnclassifiable myelodysplastic/myeloproliferative neoplasm, 1-week eruptive papular violaceous rashNACDied at 3 months
51 M/61Scalp ulceration nodularUnremarkable past medical historyNASACR
52 M/88Scalp skin noduleNAEMSDied at 3 months
53Valentin-Nogueras, 2013M/71Skin, lymph nodesHypertension, myelodysplastic syndromeLab, X-ray, CTS, R, CDied at 7 months(3)
54West, 2013M/52 LymphadenopathyNANACDied at 8 years(39)
55Lee, 2014F/45Lymph nodes, lungAsymptomatic erythematous plaques for 4 years on scalp and 1 year on axillaeCT, PETC, RAWD(15)
56Present caseM/75Subcutaneous tissue, inguinal lymph nodes, multiple organsTonsillectomy, subtotal thyroidectomy, partial prostatectomy, ACR from colorectal cancer, resection of abscess mass of buttockMRI, PET-CTC, RDied at 2 years

[i] M, male; F, female; mo., months; NA, not available; EM, electron microscopy; Lab, laboratory investigations; CT, computed tomography; MRI, magnetic resonance imaging; PET, positron emission tomography; C, chemotherapy; S, surgical excision; R, radiation therapy; allo-PBSCT, allogeneic peripheral blood stem cell transplantation; ACR, alive in complete remission; AWD, alive with disease; IGH, immunoglobulin H.

The differential diagnosis of LCS from LCH may often be challenging due to their histological and immunohistochemical similarities (40). Cytologically, however, LCS exhibits a markedly higher degree of cytological atypia and more frequent mitotic features compared with LCH (10). In the majority of cases, LCS and LCH are immunohistochemically positive for CD1a, S-100 protein and langerin (CD207), while negative for CD21 and CD35; however, LCS commonly has a higher Ki-67 index than LCH (41). Supplementary use of other diagnostic techniques demonstrates great advantages for differentiating between LCS and LCH (35). As shown in Table I, laboratory investigations, electron microscopy, ultrasound, X-ray, CT, MRI, FDG-PET and cytogenetic analysis have been used as accessory techniques in the diagnosis of LCS. In the current case, MRI was utilized during diagnosis and PET-CT was used in follow-up examinations.

Notably, the patient in the present case had an abnormal clinical history compared with other reported cases. The patient had experienced thyroid adenoma, benign prostate mass and intramucosal carcinoma. Studies of immunoglobulin heavy chain rearrangement have demonstrated that LCS may not only develop de novo, but may originate from LCH (42) or leukemia (27). Hence, it may be of great importance to analyze the clonal relationship between LCS and other types of tumor cells, such as thyroid adenoma and intramucosal carcinoma as seen in the present case. Unfortunately, such studies were not conducted with the specimen from this patient.

Another phenomenon noted in the present case was that, following the two surgical resections, the patient suffered from septic arthritis and fever. The patient had undergone a resection of a mass of the buttock 4 years prior to his presentation with the left knee mass, and the pathology had indicated an abscess. Whether the septic arthritis was a result of the LCS or was due to the patient's idiosyncrasies was not clear. Nevertheless, close attention must be paid to a patient's clinical history in clinical practice, as such information may aid in the evaluation of the patient's immune surveillance system. The occurrence of LCS has been reported previously in a patient having ongoing immunosuppression therapy following a liver transplant (16).

Due to the rarity of LCS, no standard treatment with good efficacy has been suggested to date (3). Local resection is commonly applied to isolated LCS lesions (Table I). Chemotherapies, such as a modified ESHAP (etoposide, carboplatin, cytarabine, and methylprednisolone) (20) and MAID (mesna, doxorubicin, ifosfamide, dacarbazine) (21) regimens, have been demonstrated to be effective in a proportion of patients. Radiotherapy has also been reported to be effective in certain cases. Complete remission, without signs of recurrence or metastasis for 45 months without adjuvant therapy, was achieved by a total dose of 59.4 Gy radiotherapy to a cervical lymph node LCS patient (25). In the current case, metastasis to inguinal lymph nodes was detected at ~6 months after the first surgical resection. Furthermore, multiple organs metastasis was detected following four cycles of chemotherapy with adjuvant radiotherapy. Considering the poor outcome and prognosis of LCS, more aggressive and effective standard therapies are urgently required, and a careful follow-up plan is necessary.

In summary, the present study reported a rare case of LCS originating from the subcutaneous tissue of the left knee. The diagnosis, treatment and disease progress of the case were described, which should aid in expanding the currently available knowledge concerning LCS.

Acknowledgements

The authors acknowledge Dr. Yan Song (Department of Radiology, Beijing Hospital) for providing assistance in the interpretation of the MRI data.

References

1 

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pieri SA, Stein H, Thiele J and Vardiman JW: Tumors derived from Langerhans cellsWorld Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. 4th. IARC Press; Lyon, France: pp. 278–289. 2008

2 

Wang YN, Zhou XG and Wang Z: Langerhans cell sarcoma in the cervical lymph node: A case report and literature review. Acta Haematol. 129:114–120. 2013. View Article : Google Scholar : PubMed/NCBI

3 

Valentín-Nogueras SM, Seijo-Montes R, Montalván-Miró E and Sánchez JL: Langerhans cell sarcoma: A case report. J Cutan Pathol. 40:670–675. 2013. View Article : Google Scholar : PubMed/NCBI

4 

Wood C, Wood GS, Deneau DG, Oseroff A, Beckstead JH and Malin J: Malignant histiocytosis X: Report of a rapidly fatal case in an elderly man. Cancer. 54:347–352. 1984. View Article : Google Scholar : PubMed/NCBI

5 

Elleder M, Fakan F and Hula M: Pleiomorphous histiocytic sarcoma arising in a patient with histiocytosis X. Neoplasma. 33:117–128. 1986.PubMed/NCBI

6 

Delabie J, De Wolf-Peeters C, De Vos R, Vandenberghe E, Kennes K, De Jonge I and Desmet V: True histiocytic neoplasm of Langerhans' cell type. J Pathol. 163:217–223. 1991. View Article : Google Scholar : PubMed/NCBI

7 

Tani M, Ishii N, Kumagai M, Ban M, Sasase A and Mishima Y: Malignant Langerhans cell tumour. Br J Dermatol. 126:398–403. 1992. View Article : Google Scholar : PubMed/NCBI

8 

Lauritzen AF, Delsol G, Hansen NE, Horn T, Ersbøll J, Hou-Jensen K and Ralfkiaer E: Histiocytic sarcomas and monoblastic leukemias: A clinical, histologic, and immunophenotypical study. Am J Clin Pathol. 102:45–54. 1994. View Article : Google Scholar : PubMed/NCBI

9 

Itoh H, Miyaguni H, Kataoka H, Akiyama Y, Tateyama S, Marutsuka K, Asada Y, Ogata K and Koono M: Primary cutaneous Langerhans cell histiocytosis showing malignant phenotype in an elderly woman: Report of a fatal case. J Cutan Pathol. 28:371–378. 2001. View Article : Google Scholar : PubMed/NCBI

10 

Pileri SA, Grogan TM, Harris NL, Banks P, Campo E, Chan JK, Favera RD, Delsol G, De Wolf-Peeters C, Falini B, et al: Tumours of histiocytes and accessory dendritic cells: An immunohistochemical approach to classification from the international lymphoma study group based on 61 cases. Histopathology. 41:1–29. 2002. View Article : Google Scholar : PubMed/NCBI

11 

Misery L, Godard W, Hamzeh H, Lévigne V, Vincent C, Perrot JL, Gentil-Perret A, Schmitt D and Cambazard F: Malignant Langerhans cell tumor: A case with a favorable outcome associated with the absence of blood dendritic cell proliferation. J Am Acad Dermatol. 49:527–529. 2003. View Article : Google Scholar : PubMed/NCBI

12 

Kawase T, Hamazaki M, Ogura M, Kawase Y, Murayama T, Mori Y, Nagai H, Tateno M, Oyama T, Kamiya Y, et al: CD56/NCAM-positive Langerhans cell sarcoma: A clinicopathologic study of 4 cases. Int J Hematol. 81:323–329. 2005. View Article : Google Scholar : PubMed/NCBI

13 

Jülg B, Weidner S and Mayr D: Pulmonary manifestation of a Langerhans cell sarcoma: Case report and review of the literature. Virchows Arch. 448:369–374. 2006. View Article : Google Scholar : PubMed/NCBI

14 

Ferringer T, Banks PM and Metcalf JS: Langerhans cell sarcoma. Am J Dermatopathol. 28:36–39. 2006. View Article : Google Scholar : PubMed/NCBI

15 

Lee JY, Jung KE, Kim HS, Lee JY, Kim HO and Park YM: Langerhans cell sarcoma: A case report and review of the literature. Int J Dermatol. 53:e84–e87. 2014. View Article : Google Scholar : PubMed/NCBI

16 

Diaz-Sarrio C, Salvatella-Danés N, Castro-Forns M and Nadal A: Langerhans cell sarcoma in a patient who underwent transplantation. J Eur Acad Dermatol Venereol. 21:973–976. 2007. View Article : Google Scholar : PubMed/NCBI

17 

Bohn OL, Ruiz-Argüelles G, Navarro L, Saldivar J and Sanchez-Sosa S: Cutaneous Langerhans cell sarcoma: A case report and review of the literature. Int J Hematol. 85:116–120. 2007. View Article : Google Scholar : PubMed/NCBI

18 

López-Ferrer P, Jiménez-Heffernan JA, Alves-Ferreira J, Vicandi B and Viguer JM: Fine needle aspiration cytology of Langerhans cell sarcoma. Cytopathology. 19:59–61. 2008.PubMed/NCBI

19 

Sumida K, Yoshidomi Y, Koga H, Kuwahara N, Matsuishi E, Karube K, Oshima K and Gondo H: Leukemic transformation of Langerhans cell sarcoma. Int J Hematol. 87:527–531. 2008. View Article : Google Scholar : PubMed/NCBI

20 

Yoshimi A, Kumano K, Motokura T, Takazawa Y, Oota S, Chiba S, Takahashi T, Fukayama M and Kurokawa M: ESHAP therapy effective in a patient with Langerhans cell sarcoma. Int J Hematol. 87:532–537. 2008. View Article : Google Scholar : PubMed/NCBI

21 

Uchida K, Kobayashi S, Inukai T, Noriki S, Imamura Y, Nakajima H, Yayama T, Orwotho N and Baba H: Langerhans cell sarcoma emanating from the upper arm skin: Successful treatment by MAID regimen. J Orthop Sci. 13:89–93. 2008. View Article : Google Scholar : PubMed/NCBI

22 

Zhao G, Meng L, Wu ZY, Liu Q, Zhang B, Gao RL and Zhang ZQ: Langerhans cell sarcoma involving gallbladder and perineal lymph nodes: A case report. Int J Surg Pathol. 17:347–353. 2009. View Article : Google Scholar : PubMed/NCBI

23 

Langfort R, Radzikowska E, Czarnowska E, Wiatr E, Grajkowska W, Błasińska-Przerwa K, Giedronowicz D and Witkiewicz I: Langerhans cell sarcoma with pulmonary manifestation, mediastinum involvement and bronchoesophageal fistula. A rare location and difficulties in histopathological diagnosis. Pneumonol Alergol Pol. 77:327–334. 2009.PubMed/NCBI

24 

Nakayama M, Takahashi K, Hori M, Okumura T, Saito M, Yamakawa M, Tabuchi K and Hara A: Langerhans cell sarcoma of the cervical lymph node: A case report and literature review. Auris Nasus Larynx. 37:750–753. 2010. View Article : Google Scholar : PubMed/NCBI

25 

Ratei R, Hummel M, Anagnostopoulos I, Jähne D, Arnold R, Dörken B, Mathas S, Benter T, Dudeck O, Ludwig WD and Stein H: Common clonal origin of an acute B-lymphoblastic leukemia and a Langerhans' cell sarcoma: Evidence for hematopoietic plasticity. Haematologica. 95:1461–1466. 2010. View Article : Google Scholar : PubMed/NCBI

26 

Chen YW, Chang CC, Hou PN, Yin SL, Lai YC and Hou MF: The characteristics of FDG PET/CT imaging in pulmonary Langerhans cell sarcoma. Clin Nucl Med. 37:495–497. 2012. View Article : Google Scholar : PubMed/NCBI

27 

Muslimani A, Chisti MM, Blenc AM, Boxwala I, Micale MA and Jaiyesimi I: Langerhans/dendritic cell sarcoma arising from hairy cell leukemia: A rare phenomenon. Ann Hematol. 91:1485–1487. 2012. View Article : Google Scholar : PubMed/NCBI

28 

Furmanczyk PS, Lisle AE, Caldwell RB, Kraemer KG, Mercer SE, George E and Argenyi ZB: Langerhans cell sarcoma in a patient with hairy cell leukemia: Common clonal origin indicated by identical immunoglobulin gene rearrangements. J Cutan Pathol. 39:644–650. 2012. View Article : Google Scholar : PubMed/NCBI

29 

Shimizu I, Takeda W, Kirihara T, Sato K, Fujikawa Y, Ueki T, Sumi M, Ueno M, Ichikawa N, Kobayashi H, et al: Long-term remission of Langerhans cell sarcoma by AIM regimen combined with involved-field irradiation. Rinsho Ketsueki. 53:1911–1915. 2012.(In Japanese). PubMed/NCBI

30 

Wang C, Chen Y, Gao C, Yin J and Li H: Multifocal Langerhans cell sarcoma involving epidermis: A case report and review. Diagn Pathol. 7:992012. View Article : Google Scholar : PubMed/NCBI

31 

Xu Z, Padmore R, Faught C, Duffet L and Burns BF: Langerhans cell sarcoma with an aberrant cytoplasmic CD3 expression. Diagn Pathol. 7:1282012. View Article : Google Scholar : PubMed/NCBI

32 

Yang CJ, Lee JY, Wu CC, Yin HL, Lien CT and Liu YC: An unusual pulmonary mass with mediastinal invasion and multiple intrapulmonary nodules in a 52-year-old man. Chest. 141:253–258. 2012. View Article : Google Scholar : PubMed/NCBI

33 

Chang NY, Wang J, Wen MC and Lee FY: Langerhans cell sarcoma in a chronic myelogenous leukemia patient undergoing imatinib mesylate therapy: A case study and review of the literature. Int J Surg Pathol. 22:456–463. 2014. View Article : Google Scholar : PubMed/NCBI

34 

Chen W, Jaffe R, Zhang L, Hill C, Block AM, Sait S, Song B, Liu Y and Cai D: Langerhans cell sarcoma arising from chronic lymphocytic lymphoma/small lymphocytic leukemia: Lineage analysis and BRAF V600E mutation study. N Am J Med Sci. 5:386–391. 2013. View Article : Google Scholar : PubMed/NCBI

35 

Chung WD, Im SA, Chung NG and Park GS: Langerhans cell sarcoma in two young children: Imaging findings on initial presentation and recurrence. Korean J Radiol. 14:520–524. 2013. View Article : Google Scholar : PubMed/NCBI

36 

Keklik M, Sivgin S, Kontas O, Abdulrezzak U, Kaynar L and Cetin M: Langerhans cell sarcoma of the nasopharynx: A rare case. Scott Med J. 58:e17–e20. 2013. View Article : Google Scholar : PubMed/NCBI

37 

Li Y, Li B, Tian XY and Li Z: Unusual cutaneous Langerhans cell sarcoma without extracutaneous involvement. Diagn Pathol. 8:202013. View Article : Google Scholar : PubMed/NCBI

38 

Sagransky MJ, Deng AU and Magro CM: Primary cutaneous langerhans cell sarcoma: A report of four cases and review of the literature. Am J Dermatopathol. 35:196–204. 2013. View Article : Google Scholar : PubMed/NCBI

39 

West DS, Dogan A, Quint PS, Tricker-Klar ML, Porcher JC, Ketterling RP, Law ME, McPhail ED, Viswanatha DS, Kurtin PJ, et al: Clonally related follicular lymphomas and Langerhans cell neoplasms: Expanding the spectrum of transdifferentiation. Am J Surg Pathol. 37:978–986. 2013. View Article : Google Scholar : PubMed/NCBI

40 

Zhao G, Luo M, Wu ZY, Liu Q, Zhang B, Gao RL and Zhang ZQ: Langerhans cell sarcoma involving gallbladder and peritoneal lymph nodes: A case report. Int J Surg Pathol. 17:347–353. 2009. View Article : Google Scholar : PubMed/NCBI

41 

Orii T, Takeda H, Kawata S, Maeda K and Yamakawa M: Differential immunophenotypic analysis of dendritic cell tumours. J Clin Pathol. 63:497–503. 2010. View Article : Google Scholar : PubMed/NCBI

42 

Lee JS, Ko GH, Kim HC, Jang IS, Jeon KN and Lee JH: Langerhans cell sarcoma arising from Langerhans cell histiocytosis: A case report. J Korean Med Sci. 21:577–580. 2006. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

November-2016
Volume 12 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang Y, Qu Z and Fang F: Langerhans cell sarcoma originating from left knee subcutaneous tissue: A case report and literature review. Oncol Lett 12: 3687-3694, 2016
APA
Zhang, Y., Qu, Z., & Fang, F. (2016). Langerhans cell sarcoma originating from left knee subcutaneous tissue: A case report and literature review. Oncology Letters, 12, 3687-3694. https://doi.org/10.3892/ol.2016.5194
MLA
Zhang, Y., Qu, Z., Fang, F."Langerhans cell sarcoma originating from left knee subcutaneous tissue: A case report and literature review". Oncology Letters 12.5 (2016): 3687-3694.
Chicago
Zhang, Y., Qu, Z., Fang, F."Langerhans cell sarcoma originating from left knee subcutaneous tissue: A case report and literature review". Oncology Letters 12, no. 5 (2016): 3687-3694. https://doi.org/10.3892/ol.2016.5194